Fortune Magazine — For the seventh consecutive year, Fortune Magazine ranked Johnson & Johnson/Janssen #1 in the Pharmaceuticals category on its annual World’s Most Admired Companies list, making it the highest-ranked healthcare company to appear on the top companies list in 2020. This is the 18th consecutive year the company has been included on this prestigious list. To compile the international list, Fortune magazine partners with consulting firm Korn Ferry to survey industry analysts, as well as top executives and directors from Fortune 1000, Global 500 and other major non-U.S. companies.
Fortune Magazine — For the sixth consecutive year, Fortune Magazine ranked Johnson & Johnson/Janssen number 1 in the Pharmaceuticals category on its annual World’s Most Admired Companies list, making it the highest-ranked healthcare company to appear on the top companies list in 2019. Overall, Johnson & Johnson ranked number 17 across 52 industries, and among 680 companies in 30 countries. This is the 17th consecutive year the company has been included on this prestigious list, which is based on the perceptions of 3,750 executives, corporate directors and security analysts both within and outside our industry, making it a highly-regarded report on corporate reputation.
Access to Medicine Index (ATMI) — For the fourth consecutive time, Johnson & Johnson is ranked among the top three companies working to expand global access to medicines on the 2018 Access to Medicine Index. This year’s Index highlights J&J’s unique global public health business unit, commitment to R&D for diseases of the developing world and leadership in health system strengthening. J&J is cited as one of “four leaders that consistently outperform their peers.”
Fortune Magazine — For the fifth consecutive year, Fortune Magazine ranked Johnson & Johnson/Janssen number 1 in the Pharmaceuticals category on its annual World’s Most Admired Companies list. Overall, Johnson & Johnson ranked number 17 across 52 industries, and among 680 companies in 29 countries. This is the sixteenth consecutive year the company has been included on this prestigious list, which is based on the perceptions of 3,900 executives, corporate directors and security analysts both within and outside our industry, making it a highly-regarded report on corporate reputation.
IDEA Pharma 2018 Pharmaceutical Innovation Index — Johnson & Johnson was ranked number 3 on the IDEA Pharma 2018 PII, up one spot from 2017. The PII utilizes a range of clinical, regulatory and commercial metrics to rank companies on their ability to bring products from Phase I/II to market and commercialize them successfully.
Fortune Magazine For the fourth consecutive year, Fortune Magazine ranked Johnson & Johnson/Janssen number one in the Pharmaceuticals category on its annual World’s Most Admired Companies list. Overall, Johnson & Johnson ranked number 13 among the 680 companies in 28 countries, across 51 industries included in the latest survey — up from number 15 last year. This year, Johnson & Johnson received the highest marks in our industry category on all nine reputation attributes measured in the FORTUNE survey: Innovation, People Management, Use of Corporate Assets, Social Responsibility, Quality of Management, Financial Soundness, Long-Term Investment Value, Quality of Products/Services and Global Competitiveness. FORTUNE’s Most Admired Companies list is based on the perceptions of 3,800 executives, corporate directors and security analysts both within and outside our industry, making it a highly-regarded report on corporate reputation.
Fortune Magazine For the third consecutive year, Fortune Magazine ranked Johnson & Johnson/Janssen number one in the Pharmaceuticals category on its annual World’s Most Admired Companies list. This list is based on the perceptions of 4,000 executives, corporate directors and security analysts both within and outside the pharmaceuticals industry. Overall, Johnson & Johnson ranked number 15 among all 340 companies, across all industries. Johnson & Johnson is also one of only a select few companies based in the United States that has been on the list for more than 30 consecutive years.
InterbrandHealth Janssen was named one of the most valuable corporate brands in the biopharmaceutical industry by InterbrandHealth in its new report of the world’s “Best Pharma Brands.” Janssen ranked number four in this inaugural study, which examines what value means to healthcare professionals and illustrates the influence a corporate brand has in conveying that value. The report applauds Janssen for its ability to build strong, lasting relationships with practitioners, payers and policymakers, while delivering transformative healthcare solutions for patients.
IDEA Pharma For the fourth consecutive year, IDEA Pharma, an industry-leading consultancy, ranked Johnson & Johnson/Janssen number one, among 30 pharmaceutical companies, in its sixth annual Productive Innovation Index (PII). The PII ranking is unique because it not only measures a company’s ability to discover and develop solutions for patients, but also its ability to commercialize its innovations.
BioSpace Johnson & Johnson/Janssen was named the top pharmaceutical company to work for by BioSpace, a leading industry platform for life sciences professionals. The report is based on Fortune Magazine’s 2016 World’s Most Admired Companies list, where Johnson & Johnson/Janssen was ranked number one in the Pharmaceuticals category for the third consecutive year.
Fortune Magazine Our focus on providing innovative therapies and services to transform the lives of patients was recognized by Fortune Magazine, which ranked Johnson & Johnson as the number one company in the Pharmaceuticals category on its list of the World's Most Admired Companies for the second year in a row. Across all categories, Johnson & Johnson ranked number 11 – up from number 19 last year. Fortune recognized us for becoming one of the first healthcare companies to agree to share clinical trial data and diagnostic tests with researchers at Yale University. Fortune also noted that Johnson & Johnson announced it was testing an Ebola vaccine, positioning itself for a new role in world health.
IDEA Pharma For the third consecutive year, IDEA Pharma named Johnson & Johnson as the Most Productive Global Pharmaceutical Company in its fifth annual Productive Innovation Index (PII). The PII measures and ranks companies based upon their ability to not only discover but also commercialize new medicines.
Access To Medicine Index (ATMI) Johnson & Johnson ranked number three in the fourth biennial Access to Medicine Index (ATMI), which documented significant industry-wide progress during the period June 2012-May 2014, toward improving access to medicines for the millions of people in need of treatment and care who live in low- and middle-income countries. The report’s impartial review of our efforts compared to those of the rest of the industry provides valuable feedback for our future endeavors, including areas for improvement. It also is a key resource for our stakeholders and serves as the benchmark for our access strategies around the world.
Salveson Stetson Group Johnson & Johnson was identified as the most desirable "Big Pharma" employer for its innovation in research and development (R&D) according to a survey by Salveson Stetson Group, a retained executive search firm that works in the life sciences space. More than 220 pharmaceutical industry employees were surveyed. The reason cited most frequently for ranking a company high as an employer was innovation, named by 62 percent of respondents. Other factors mentioned were portfolio (45 percent), corporate image (42 percent), work environment (42 percent) and pipeline (42 percent). Compensation was one of the least important attributes, named by only 18 percent of respondents.
Fortune Magazine Our focus on providing innovative therapies and services to transform the lives of patients was recognized by Fortune Magazine, which ranked Johnson & Johnson as the number one company in the Pharmaceuticals category on its list of the World’s Most Admired Companies. This was up from number four the previous year. Johnson & Johnson improved or maintained its ranking on all nine attributes of reputation. Across all categories, Johnson & Johnson ranked number 19 – up from number 23 the previous year – and it was the only healthcare company to make the list of the Top 50. It is also one of a select few U.S.-based companies to be included among Fortune’s Most Admired Companies for the past 30 years.
IR Magazine Johnson & Johnson won the 2014 award for best IR practice in the Pharmaceutical sector from IR Magazine. The awards are based on a rigorous, open-ended survey of the investment community. This was the second year in a row that the team was recognized by the magazine for their outstanding work.
IDEA Pharma In 2013/2014, IDEA Pharma named Johnson & Johnson as the Most Productive Global Pharmaceutical Company in its fourth annual Productive Innovation Index (PII). The PII measures and ranks companies based upon their ability to not only discover but also commercialize new medicines.